A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antineoplastic activity of APS03118 administered orally in participants with RET-altered solid tumors.

Inclusion Criteria:Male or female patients aged 18 years or olderHave histological or cytological confirmation of unresectable locally advanced or metastatic solid tumors harboring oncogenic RET mutations or fusions confirmed by NGS. Site may identify patients with a RET-mutated or RET-fusion solid tumor before the formal screening.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.Resolution of all toxic effects of prior therapies to Grade 1 or below according to NCI CTCAE version 5.0 (except alopecia or Grade 2 neuropathy);Patients with asymptomatic brain metastases if they have been previously treated, demonstrated no progression at least for 1 months before Screening, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before ScreeningAdequate organ functionExclusion Criteria:Have a locally advanced solid tumor that is a candidate for curative surgery treatment through radical surgery and/or radiotherapy.Have an active fungal, bacterial, and/or active untreated viral infectionThe patient has a serious pre-existing medical condition(s)Have received or will receive a COVID-19 vaccine within 1 month before the first dose of APS03118.